Φορτώνει......
Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax offers a Therapeutic Strategy for Acute Myeloid Leukemia
Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR+VEN), curren...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Leukemia |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7484148/ https://ncbi.nlm.nih.gov/pubmed/32094466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0764-6 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|